AUTL
Autolus Therapeutics plc
1.80$
-2.2%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -63.7% | +0.0% | -7.8% | +0.0% | -19.1% | +29.7% | +4.0% | -30.7% | -3.6% | +563.5% | -82.8% | -12.1% | +4.0% | +9.4% | -13.3% | +132.1% | -40.6% | -33.4% | +511.5% | -85.7% | -23.7% | -7.8% | -100.0% | – | +61.5% | -66.2% | -100.0% | – | +337.2% | +468.5% | -100.0% | – | – | +30,872.4% | +132.9% | +1.3% | +14.4% | +8.1% | +74.3% | – | |
| – | -76.8% | +0.0% | +28.4% | +0.0% | +91.0% | +35.3% | -23.8% | +13.9% | +75.4% | +27.4% | +16.0% | +4.3% | +7.5% | +6.5% | +0.1% | +7.1% | +15.5% | -20.6% | +4.6% | +0.5% | +22.7% | -94.8% | -7.2% | +1,861.0% | -95.4% | +10.8% | -20.4% | +0.9% | +16.4% | +1.7% | +4.9% | -35.7% | +11,255.0% | -87.0% | +36.2% | +17.2% | -11.7% | -2.9% | -16.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -128.8% | – | – | – | – | -122.9% | – | – | – | – | – | – | – | +1,428.5% | – | |
| – | -66.4% | +0.0% | +31.2% | +0.0% | -100.0% | – | -24.2% | +14.5% | +74.5% | +27.4% | +16.0% | +4.3% | +7.4% | +6.7% | +0.2% | +7.1% | +15.2% | -20.6% | +4.6% | +0.5% | +23.0% | -14.5% | +12.5% | -1.5% | -29.0% | +2.5% | +21.3% | -2.8% | -22.2% | +21.9% | +19.4% | +10.1% | +25.3% | -47.1% | +2.6% | +1.7% | +27.6% | -40.4% | +31.5% | – | |
| – | -67.7% | +0.0% | +73.5% | +0.0% | +28.4% | +16.8% | +57.1% | +6.9% | +4.4% | +25.9% | +19.0% | -24.3% | -2.0% | -9.7% | +11.8% | +15.7% | -8.5% | -6.6% | -14.0% | +14.7% | -24.6% | +27.7% | +3.5% | -0.5% | -10.0% | +25.3% | +19.8% | -4.6% | +48.2% | +15.6% | +20.5% | +24.8% | +146.7% | -56.2% | +2.5% | +19.9% | -1.3% | +11.6% | +3.0% | – | |
| – | -89.3% | +0.0% | +73.6% | +0.0% | +324.0% | -40.9% | -76.4% | +254.2% | +317.1% | +26.9% | +16.9% | -4.3% | +9.3% | -0.8% | +2.4% | +9.0% | +9.8% | -17.3% | -0.3% | +3.1% | +16.6% | -15.7% | +16.5% | -1.3% | -29.3% | +7.3% | +27.6% | -3.2% | -8.9% | +20.3% | +25.3% | +14.8% | +52.5% | -45.5% | +2.5% | +11.2% | +11.1% | -14.2% | +12.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -100.0% | – | – | – | -100.0% | – | – | – | – | +0.0% | +1,130.9% | -30.8% | +54.5% | -14.3% | -99.1% | +5,159.6% | -55.0% | -58.5% | +291.1% | -45.8% | +12.9% | +62.0% | +1.1% | +2.2% | +86.9% | +41.9% | +2.3% | -0.1% | +500.9% | -36.0% | -47.2% | +5.0% | +188.6% | -67.1% | -32.7% | +54.0% | +116.8% | -51.3% | -75.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -4.4% | +90.0% | +12.0% | -171.0% | – | – | – | – | – | – | – | – | -103.9% | – | -152.5% | – | -100.1% | – | -56.9% | +6,545.5% | +52.2% | -82.2% | +34.0% | -322.0% | – | -46.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.